PIB TrackerNPPA orders compliance checks on 137 anti-cancer drugs
Four days after the revised MRPs took effect, the pricing authority told State Drug Controllers to monitor margins on 137 anti-cancer drugs and report back by 16 November, with overcharging proceedings under DPCO 2013 for violators.
What happened
- NPPA directed strict monitoring of Trade Margin Rationalisation on 137 non-scheduled anti-cancer drugs, notified by Gazette Order of 17 October 2026.
- Revised prices have applied since 9 November 2026; the latest lists, based on submissions up to 11 November, are on the NPPA website and the Pharma Sahi Daam app.
- Manufacturers, retailers, dealers, stockists and hospitals must charge the revised prices and display updated lists.
- State Drug Controllers must monitor compliance and file Action Taken Reports by 16 November 2026.
- Violations may draw overcharging proceedings under DPCO, 2013; helpline 1800-111-255.
For Prelims
- NPPA: the Department of Pharmaceuticals' independent regulator for drug pricing, working to keep medicines available and affordable; the Department sits in the Ministry of Chemicals and Fertilizers.
- Trade Margin Rationalisation: capping the margin between the price a manufacturer charges and the MRP a patient pays; here capped at 30 per cent of MRP for 137 identified non-scheduled anti-cancer drugs.
- Paragraph 19, DPCO 2013: lets prices be fixed in extraordinary circumstances in the public interest, and is the power behind the 30 per cent cap (PRIDs 2242923, 2333536).
- Non-scheduled formulations: drugs outside Schedule I of DPCO 2013, which is based on the National List of Essential Medicines; makers may not raise MRP by more than 10 per cent in 12 months (PRIDs 2242923, 2333536).
- 2019 pilot: margins on 42 anti-cancer drugs were capped, cutting the MRP of 526 brands (PRIDs 2324743, 2321092).
- Expert committee: constituted under the Directorate General of Health Services; it recommended the 137 drugs, and the list is to be updated periodically (PRIDs 2324743, 2333536).
- Reported cuts: the highest reduction in MRP reported by companies was 96.45 per cent, as of 4 November and again as of 8 November; reporting companies rose from 70 to 85 (PRIDs 2333536, 2334268).
- Pharma Sahi Daam: the NPPA app and portal for checking prices and lodging overcharging complaints.
For UPSC: NPPA monitors TMR on 137 non-scheduled anti-cancer drugs: Gazette 17 October 2026; effective 9 November; 30 per cent MRP cap (Para 19, DPCO 2013); State reports due 16 November.
What it is NOT: The release gives no price figures, no count of companies that have filed revised MRPs, and no number of inspections, complaints or overcharging cases. It does not say what a Drug Controller must check, what penalty follows, or how a hospital's own supply is to be verified. It does not repeat the 30 per cent cap or the drug list, and says nothing on shortages beyond naming the complaint channels.
For Mains
Syllabus: GS2.13 · GS2.9 · Linkage L1
Anchor
A price cap works only if someone checks the shelf. The Authority fixes prices centrally, but sale happens in pharmacies and hospital counters that State Drug Controllers oversee.
Substantiation (data)
The order covers 137 drugs and took effect on 9 November 2026. Companies reported cuts of up to 96.45 per cent, and reporting companies rose from 70 to 85 between 4 and 8 November. Controllers must report by 16 November.
Position
Splitting roles keeps the Authority on price-setting and the States on inspection, where the stock and the pharmacies are. A dated reporting deadline gives the Centre one comparable snapshot across States.
Counterpoint
Compliance depends on State capacity that varies, and patients rarely compare the printed MRP with a list. The release names no penalty, and does not say how direct hospital purchases will be checked.
Way forward
Publish the Controllers' reports by State, test sample purchases at hospital pharmacies, keep the shortage helpline visible, and watch whether the 2019 pilot's savings persisted before claiming the new ones.
Conclusion
The 16 November reports will show whether the cap changed what patients pay or only what lists say. That is the evidence the next review of the drug list should use.
Deploys into: Drug price regulation and DPCO 2013 · Health financing and out-of-pocket expenditure · Centre-State regulatory coordination · Statutory regulators and compliance monitoring
Ministry of Chemicals and Fertilizers · 2026-11-13 · PRID 2335722 · PIB source ↗